NFE2L2 and lip and oral cavity carcinoma: Our study proposes a combined therapeutic strategy in which the application of an NRF2 inhibitor in conjunction with PDT significantly enhances PDT efficacy, effectively preventing the malignant progression of OLK to oral cancer.